Global Endocrinology Drugs Market Report 2018 - Forecast to 2022 Featuring Leading Vendors - Abbvie, Merck, Novo Nordisk & Pfizer - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Global Endocrinology Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The Global Endocrinology Drugs Market to grow at a CAGR of 6.48% during the period 2018-2022.
Global Endocrinology Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of endocrinology drugs.
According to the report, one driver influencing this market is the increasing incidence of endocrine disorders. The increase in incidence of endocrine disorders may be due to the rising aging population globally. A trend that is generally seen in the incidence of endocrinology disorders such as diabetes is that the incidence is generally higher in low-and middle-income countries.
The use of biosimilars for endocrine disorders to be one of the major trends in the market A biosimilar is a biologic product that is approved based on demonstrating that it is similar to an approved biologic product, known as a reference product.
Further, the report states that one challenge affecting this market is the reimbursement challenges. Most endocrine disorders pose a significant economic burden on patients as well as on healthcare systems. Physicians and patients have concerns regarding inadequate reimbursement for most endocrine disorders, including diabetes.
Key vendorsAbbvie Merck Novo Nordisk Pfizer
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZINGMarket sizing 2017 Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 08: MARKET SEGMENTATION BY THERAPY AREAComparison by therapy area Diabetes drugs Thyroid hormone disorder drugs hGH Testosterone replacement therapy Others Market opportunity by therapy area
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDSAssociation between obesity and endocrine disorders Use of biosimilars for endocrine disorders
PART 14: VENDOR LANDSCAPEOverview Landscape disruption
PART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/2fp76n/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005849/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/26/2018 01:36 PM/DISC: 09/26/2018 01:36 PM